Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9661057 | 0.86 | ADRB1 (0.48) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL7289414 | 0.84 | ADRB1 (0.60) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL21775617 | 0.83 | ADRB1 (0.45) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL4236119 | 0.80 | ADRB1 (0.52) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL6833323 | 0.79 | ADRB1 (0.69) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7930799 | 0.78 | LMNA (0.63) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL5318404 | 0.76 | ADRB1 (0.51) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL2585659 | 0.74 | PPARG (0.39) | ADRB1LMNACYP2D6CYP1A2ADRB2 | |
| Betaxolol SCHEMBL23531 | 0.74 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL23530 | 0.74 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115337267-B | Preparation method and application of acid-responsive drug delivery platform based on liposome nano vesicles | 中国科学技术大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115337267-A | Preparation method and application of acid-responsive drug delivery platform based on liposome nano-vesicles | 中国科学技术大学 | 2022-11-15 | — | — | CN | disclosed |
| EP-3853305-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3852732-A1 | PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3787642-A1 | MATRIX BOUND VESICLES (MBVS) CONTAINING IL-33 AND THEIR USE | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3716968-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | Anavex Life Sciences Corp. (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| WO-2020061295-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061284-A1 | PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005018561-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1451577-A2 | SOLUBLE CD40L(CD154) AS A PROGNOSTIC MARKER OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1386165-A2 | INFLAMMATORY MARKERS FOR DETECTION AND PREVENTION OF DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003094856-A2 | 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER AND THERAPEUTIC TARGET | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003040691-A2 | SOLUBLE CD40L(CD154) AS A PROGNOSTIC MARKER OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1216037-A2 | METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS USING MPL PATHWAY INHIBITORY AGENTS | Emory University (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002048715-A2 | INFLAMMATORY MARKERS FOR DETECTION AND PREVENTION OF DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002038794-A2 | CARDIOVASCULAR DISEASE DIAGNOSTIC AND THERAPEUTIC TARGETS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2001021163-A2 | METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS USING MPL PATHWAY INHIBITORY AGENTS | EMORY UNIVERSITY (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | ADRB1 208/4885LMNA 2085/4885CYP2D6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.